The biotech company restored a sometime positive balance in the stock market in 2024 after receiving support from the US pharmaceutical regulator, FDA, for the start of phase III trials on one of its flagship drugs, vafidemstat.
News from America again pushed up Oryzon prices. The bullish momentum gained today pushed the intraday high they return to a positive balance in 2024 to their actions.
Before the opening of the day
To continue reading, use Premium
Try it for €1 the first month
and enjoy unlimited access to all Expansión web content
Or register with your Google account in two clicks